{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:46:48Z","timestamp":1782251208294,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.vaccine.2026.128581","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:56:40Z","timestamp":1776560200000},"page":"128581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety of the adjuvanted herpes zoster subunit vaccine in people over 18\u00a0years of age living with HIV: A phase 4 multicentre study"],"prefix":"10.1016","volume":"82","author":[{"given":"Matilde Zornoza","family":"Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Fern\u00e1ndez","family":"Prada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Cienfuegos","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Madrid","family":"Gomariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley Beatriz P\u00e9rez","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel Alejandra L\u00f3pez","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Ca\u00f1adilla","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime Jes\u00fas P\u00e9rez","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128581_bb0005","series-title":"Varicella-zoster virus: Virology and clinical management","first-page":"246","article-title":"Clinical manifestations of herpes zoster","author":"Oxman","year":"2000"},{"key":"10.1016\/j.vaccine.2026.128581_bb0010","unstructured":"Herpes zoster vaccination working group from Report on the Vaccination Programme and Registry. Public Health Commission of the Interterritorial Council of the National Health System. Ministry of Health, 2021 (reviewed Recommendations Section in October 2023). https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/programasDeVacunacion\/docs\/HerpesZoster_RecomendacionesVacunacion.pdf [accessed May 1, 2025]."},{"key":"10.1016\/j.vaccine.2026.128581_bb0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2334-13-170","article-title":"Similar herpes zoster incidence across europe: results from a systematic literature review","volume":"13","author":"Pinchinat","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128581_bb0020","first-page":"S13","article-title":"Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence","volume":"109","author":"Oxman","year":"2009","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.vaccine.2026.128581_bb0025","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annepidem.2005.12.002","article-title":"Gender as independent risk factor for herpes zoster: a population based study","volume":"16","author":"Opstelten","year":"2006","journal-title":"Ann Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128581_bb0030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/09564624251324975","article-title":"Shingles in HIV: outcome and discovery","volume":"36","author":"Guechchati","year":"2025","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.vaccine.2026.128581_bb0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.puhe.2018.10.015","article-title":"Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain","volume":"167","author":"Mareque","year":"2019","journal-title":"Public Health"},{"key":"10.1016\/j.vaccine.2026.128581_bb0040","author":"European Medicines Agency"},{"key":"10.1016\/j.vaccine.2026.128581_bb0045","author":"Instituto Nacional de Estad\u00edstica (INE)"},{"key":"10.1016\/j.vaccine.2026.128581_bb0050","author":"Bernal-Delgado"},{"key":"10.1016\/j.vaccine.2026.128581_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128581_bb0060","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128581_bb0065","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2026.128581_bb0070","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.vaccine.2019.11.058","article-title":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","volume":"38","author":"Tavares-Da-Silva","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128581_bb0075","author":"U.S. Department of Health and Human Services. Food and Drug Administration"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128581_bb0080","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/21645515.2018.1556078","article-title":"Compliance with vaccination schedules","volume":"15","author":"Hadjipanayis","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128581_bb0085","first-page":"5","article-title":"The nocebo effect as a source of bias in the assessment of treatment effects","volume":"8","author":"Wartolowska","year":"2019","journal-title":"F1000Res"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128581_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.43955","article-title":"Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: a systematic review and meta-analysis","volume":"5","author":"Haas","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128581_bb0095","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1080\/21645515.2020.1741312","article-title":"Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials","volume":"16","author":"Colindres","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128581_bb0100","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2341456","article-title":"Immunogenicity and safety of live attenuated and recombinant\/inactivated varicella zoster vaccines in people living with HIV: a systematic review","volume":"20","author":"Carta","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128581_bb0105","article-title":"Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance","volume":"9","author":"Fiore","year":"2021","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128581_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0313889","article-title":"Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations","volume":"19","author":"Marra","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128581_bb0115","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2278362","article-title":"Recombinant zoster vaccine in immunocompetent and immunocompromised adults: a review of clinical studies","volume":"19","author":"Mwakingwe-Omari","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128581_bb0120","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/bloodadvances.2020003749","article-title":"Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation","volume":"5","author":"Baumrin","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128581_bb0125","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1111\/ajt.16534","article-title":"Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients","volume":"21","author":"Hirzel","year":"2021","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128581_bb0130","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.japh.2020.11.011","article-title":"Impact of a pharmacist-driven recombinant zoster vaccine administration program","volume":"61","author":"Porter","year":"2021","journal-title":"J Am Pharm Assoc"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128581_bb0135","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/j.vaccine.2022.03.006","article-title":"Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021","volume":"40","author":"LaMori","year":"2022","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:52:29Z","timestamp":1782247949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"alternative-id":["S0264410X26003890"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128581","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of the adjuvanted herpes zoster subunit vaccine in people over 18\u00a0years of age living with HIV: A phase 4 multicentre study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128581"}}